Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN5601-K
- Development stage
- Phase 1
- Lead developer
- Children's Hospital, Zhejiang University School of Medicine
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
KN5601-K is a second-generation chimeric antigen receptor (CAR) natural killer (NK) cell therapy that simultaneously targets CD19 and B-cell maturation antigen (BCMA). Developed by The Children's Hospital of Zhejiang University School of Medicine, this investigational therapy is designed to treat pediatric B cell-mediated autoimmune diseases by depleting both B cells and plasma cells. By targeting two distinct antigens, KN5601-K aims to achieve more thorough depletion of the pathogenic B-cell lineage than single-target CAR therapies, potentially offering improved efficacy in refractory cases of systemic lupus erythematosus, steroid-resistant nephrotic syndrome, and other autoimmune conditions.
- Other names
- anti-CD19/BCMA CAR NK cellsCD19/BCMA CAR-NK cells
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on KN5601-K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN5601-K.